Inactive Instrument

The Valens Company Inc.

VLNS

CA91914P6030

The Valens Company Inc. Reiterates Revenue Guidance for First Quarter 2021

February 24, 2021 at 06:06 pm

The Valens Company Inc. reiterated revenue guidance for the first quarter 2021. For the period, the company projected revenue to be between $19 million to $23 million.

Latest news about The Valens Company Inc.

The Valens Company Inc.(NasdaqCM:VLNS) dropped from NASDAQ Composite Index	23-01-17	CI
SNDL Inc. completed the acquisition of remaining 91.9% stake in The Valens Company Inc..	23-01-16	CI
Valens Gets Final Court Order Approving Proposed Arrangement With SNDL	23-01-03	MT
The Valens Co Obtains Final Court Order Approving Proposed Arrangement With SNDL	23-01-03	MT
The Valens Company Obtains Final Court Order Approving Proposed Plan of Arrangement With SNDL	23-01-03	MT
The Valens Company Granted Additional 180-Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	22-12-14	MT
North American Morning Briefing : Investors Wary -2-	22-12-14	DJ
The Valens Co Brief: Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule	22-12-14	MT
Valens Gets Additional 180-Day Period to Regain Nasdaq Compliance	22-12-14	MT
The Valens Company Brief: Says Shareholders Vote in Favour of the Arrangement with SNDL	22-11-29	MT
The Valens Company Brief: Both Institutional Shareholder Services and Glass Lewis & Co. Recommend Shareholders of Co Vote For Proposed Arrangement With SNDL Inc.	22-11-22	MT
Earnings Flash (VLN) VALENS SEMICONDUCTOR Posts Q3 Revenue $23.1M, vs. Street Est of $22.7M	22-11-09	MT
Earnings Flash (VLN) VALENS SEMICONDUCTOR Posts Q3 EPS $-0.02, vs. Street Est of $-0.08	22-11-09	MT
The Valens Company Inc. Secures Sales Licence for Greater Toronto Area Beverage Facility	22-11-02	CI
The Valens Company Brief: Announcing Mailing and Filing of Circular for Special Meeting of Shareholders To Approve Arrangement With SNDL Inc.	22-10-27	MT
The Valens Company Buy Rating Reiterated at Stifel GMP Following FQ3 Results; Price Target Kept at C$1.20	22-10-14	MT
Sector Update: Consumer Stocks Close Near Thursday Session Highs	22-10-13	MT
Sector Update: Consumer Stocks Moderately Higher Compared with Most Other Thursday Sectors	22-10-13	MT
The Valens Company Up After Reporting Third Quarter Fiscal 2022 Financial Results	22-10-13	MT
The Valens Company Says Q3 Net Revenue Fell 15.4% to $20.3 Million	22-10-13	MT
The Valens Company Brief: Co Has Entered into an Arrangement Agreement to be Acquired by SNDL	22-10-13	MT
The Valens Company Brief: Q3 Net revenue decreased 15.4% to $20.3 million in Q3 2022	22-10-13	MT
The Valens Company Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-13	CI
The Valens Company Inc. Withdraws All Previously Given Financial Guidance	22-10-13	CI
The Valens Company Inc.(TSX:VLNS) dropped from S&P Global BMI Index	22-09-19	CI

The Valens Company Inc. is a Canada-based company, which is engaged in the manufacturing of cannabinoid-based products. It operates through two segments: Canada and United States and International. Canada segment includes all business-to-business and business-to-consumer activity within Canada. This includes toll processing and co-packing, product sales, and analytical testing. United States and International segment include all activity related to the Green Roads CBD health and wellness manufacturing facility in Florida, United States. Its products are formulated for the recreational, health and wellness, and medical consumer segments and are offered across all cannabis product categories. It also manufactures, distributes, and sells a range of cannabidiol (CBD) products in the United States through its subsidiary Green Roads, Inc. (Green Roads), and distributes medicinal cannabis products to international markets through its subsidiary Valens Australia Pty Ltd (Valens Australia).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+41.99%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+17.81%	246B
ROCHE HOLDING AG	+0.25%	225B
NOVARTIS AG	+10.55%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals